Abstract
Importance: While lower urinary tract symptoms (LUTS) are common, particularly among children and young adults, the genetic and familial underpinnings of these symptoms are not well established. Objective: To determine the familial aggregation and heritability of LUTS in a nationwide cohort of children and young adults. Design, Setting, and Participants: This population-based cohort study utilized data from Swedish national registers, including all live-born singleton children in Sweden from January 1, 1995, onward. The study population comprised children and young adults identified through Swedish national databases. Methods: Familial aggregation was quantified by calculating relative recurrence risks (RRs) and associated 95% confidence intervals (CIs) among siblings and cousins of individuals affected by LUTS. Heritability was estimated using Falconer's Liability Threshold Model. Results: Significant familial aggregation was observed, with sibling RRs of 6.53 (95% CI, 2.09-20.38; P = .001) for voiding LUTS and 6.53 (95% CI, 2.09-20.38; P = .001), and 55% (95% CI, 45.5%-64.7%) heritability for storage LUTS using a narrow ICD-medication definition. Cousin recurrence risks were notably lower. Sex-specific analyses indicated higher aggregation in same-sex sibling pairs. Broader definitions yielded slightly lower heritability estimates (48% for storage LUTS, 40% for voiding LUTS). Results: Strong familial aggregation of LUTS was observed, with significantly elevated recurrence risks among siblings, particularly same-sex pairs, supporting a genetic contribution. Storage LUTS exhibited higher heritability compared to voiding LUTS. Conclusions: These results underscore a substantial genetic contribution to LUTS in young individuals, suggesting potential for targeted genetic research, early interventions, and personalized risk assessments based on familial history.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant from the Swedish Research Council (2021-02846) and the Beatrice and Samuel A. Seaver Foundation, Icahn School of Medicine at Mount Sinai, New York, NY.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Ethical Review Board in Stockholm, Sweden.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos